Welcome to our dedicated page for Athira Pharma SEC filings (Ticker: ATHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Athira Pharma, Inc. (NASDAQ: ATHA) SEC filings page brings together the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Athira, which has announced a name change to LeonaBio, Inc. with a future ticker "LONA," uses filings such as Forms 8-K and 8-K/A to report material events related to its operations, capital structure and key licensing agreements.
Recent filings describe a 10-for-1 reverse stock split of common stock, implemented through a certificate of amendment in Delaware, and subsequent confirmation from The Nasdaq Stock Market that Athira regained compliance with the minimum bid price requirement. Other 8-K filings detail a private placement financing involving common stock, pre-funded warrants and accompanying common warrants, with gross proceeds expected to be approximately $90 million, and outline associated registration rights for investors.
Filings also cover Athira’s exclusive licensing arrangements for lasofoxifene with Sermonix Pharmaceuticals and Ligand Pharmaceuticals, including the assumption of responsibility for the global Phase 3 ELAINE-3 trial outside specified retained territories. These documents provide insight into how the company structures rights to develop, manufacture and commercialize oral forms of lasofoxifene and how it coordinates with partners.
On this page, users can review Athira’s current reports to understand how financing terms, warrant structures, reverse stock split mechanics and licensing obligations interact with its clinical programs in metastatic breast cancer and ALS. Stock Titan’s platform adds AI-powered summaries to help explain the key points of lengthy filings, highlight important dates and thresholds, and make it easier to interpret how each filing may relate to Athira/LeonaBio’s broader strategic and clinical plans.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock, with an exercise price of $9.54 per share and expiration on April 8, 2036. These options were granted at no upfront cost as compensation, not through an open-market purchase.
According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Panzara continues to serve as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds 28,000 derivative securities tied to LeonaBio common stock.
LeonaBio, Inc. reported that its Chief Scientific Officer, Kevin Church, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was received as a compensation-related grant, not an open-market purchase or sale. According to the grant terms, the options are scheduled to vest monthly over 48 months, as long as Church continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Barbara Kosacz received a grant of stock options representing rights to buy 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
According to the grant terms, the 28,000 option shares are scheduled to vest in equal monthly installments over 24 months from the grant date, as long as Kosacz continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Grant Pickering received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. This is a compensation-related award, not an open-market trade.
The filing shows Pickering holding 28,000 options after the transaction. According to the footnote, the options vest monthly over 24 months from the grant date, contingent on continued service as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan.
LeonaBio, Inc. director Romano Kelly A received a grant of stock options covering 28,000 shares of common stock on April 9, 2026. The options carry an exercise price of $9.54 per share and expire on April 8, 2036. According to the award terms, the 28,000 underlying shares are scheduled to vest in equal monthly installments over 24 months, contingent on Kelly continuing as a Service Provider under LeonaBio's 2026 Equity Incentive Plan.
LeonaBio, Inc. director James A. Johnson received a grant of stock options covering 28,000 shares of common stock. The options carry an exercise price of $9.54 per share and expire on April 8, 2036, and represent compensation rather than an open-market purchase.
These options are scheduled to vest monthly over 24 months on the monthly anniversaries of the grant date, as long as Johnson continues as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036. The award vests monthly over 24 months, so Edelman earns portions of the grant gradually as he continues to serve as a service provider. Following this grant, he holds stock options for 28,000 underlying shares directly.
LeonaBio, Inc. reported that Chief Medical Officer Javier San Martin received a grant of stock options covering 350,000 shares of common stock. The options have an exercise price of $9.54 per share, expire on April 8, 2036, and were awarded as compensation.
According to the grant terms, the options vest in equal monthly installments over 48 months from the grant date, so long as San Martin continues to serve as a Service Provider under LeonaBio's 2026 Equity Incentive Plan. This is a derivative award, not an open-market purchase or sale.
LeonaBio, Inc. director John M. Fluke Jr. received an option grant covering 28,000 shares of common stock. The stock option has an exercise price of $9.54 per share and expires on April 8, 2036.
The award was granted as compensation (not an open‑market purchase) and vests in equal monthly installments over 24 months from the grant date, contingent on Mr. Fluke continuing to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this award, he holds options for 28,000 shares directly.
LeonaBio, Inc. reported that its General Counsel and Chief Compliance Officer, Mark Worthington, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
The award was classified as a grant or other acquisition of a derivative security, with 300,000 options held directly after the transaction. According to the grant terms, the underlying shares are scheduled to vest monthly over 48 months, subject to his continued service as a provider under LeonaBio’s 2026 Equity Incentive Plan.